Arrowhead Research ARWR Non-cash interest expense on liability related to the sale of future royalties
Non-cash interest expense on liability related to the sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept arwr:NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's non-cash interest expense on liability related to the sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's non-cash interest expense on liability related to the sale of future royalties?
- Arrowhead Research (ARWR) reported non-cash interest expense on liability related to the sale of future royalties of $8.83M in Q1 2026.
- How has Arrowhead Research's non-cash interest expense on liability related to the sale of future royalties changed year-over-year?
- Arrowhead Research's non-cash interest expense on liability related to the sale of future royalties increased by 60.6% year-over-year, from $5.5M to $8.83M.
- What does non-cash interest expense on liability related to the sale of future royalties mean?
- Non-cash interest costs related to debt obligations secured by future royalty payments.
- How do you interpret non-cash interest expense on liability related to the sale of future royalties?
- Increases suggest higher debt servicing costs or specific financing structures that defer cash payments.
- How does non-cash interest expense on liability related to the sale of future royalties compare across companies?
- Specific to biotech companies that monetize future drug royalties to fund current operations.